, - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

  • th3k33p3r24 th3k33p3r24 Oct 24, 2013 5:57 PM Flag

    Wishful thinking?

    Maybe this is just wishful thinking and the stock will tank tomorrow... who knows? But in looking at the recent action, I note the following:
    - AMPE completes a Phase 3 on Ampion, but not all the results (in detail) are publicly disclosed
    - Pre-BLA mtg set for 10/29
    - Emerging Growth Equities does a very detailed (28 page?) report apparently getting into details of the Ampion Phase 3 - and gives a $14 price target (imspecialed seems to have some insight)
    - AMPE enters into a 5 year (!) $11M (!) supply contract for HSA
    - Comparables for similar companies shows that AMPE is valued at about 25% of market, and maybe 10% of market with a very positive FDA meeting
    - Large (for AMPE) institutional investment over 2 days jacks the price by over 20%

    So OK... Would AMPE enter into a supply agreement if they weren't confident? Does the agt have a "subject to FDA approval" clause? Did EGE get far enough into the Phase 3 result to opine on the FDA meeting? Is a significant IB firm noticing and snarfing up shares prior to analyst coverage, and a $20+ PT? Are other institutions taking the EGE report seriously? ... and so many more questions...!

    With a very positive FDA mtg $11/$12/$14, etc would still be VERY cheap. Could we see $25 with a "breakthrough therapy" designation? More? Or is this wishful thinking and this will come crashing down tomorrow or post-meeting if the results aren't astounding?

    I tend to think that the cat is (finally) getting out of the bag.... and we've only scratched the surface of the explosion in this stock. I sure hope I'm right... and Agnew's (and other longs' prayers are answered!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ...well spoken. I feel confident that AMPE will get some form of fast track/accelerated approval decision from the FDA. A $2 Billion+ market cap is an achievable goal, and that would put us near $50.00/share. A higher yet market cap is not a pipe dream either. As I've stated before, Ampion could be considered a "miracle drug" in time.

 
AMPE
3.56+0.03(+0.85%)Oct 1 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.